Biotech Values

[DewDiligence]

Re AGIX:

>> I guess we'll have to see what the final cart II data show to see if they cherry picked in this interim analysis… I think the bottom line for agix is the arise-events trial will be the new binary event and a HUGE one at that. Unless they agree to merge in the interim. <<

If we accept the premise that the interim data reported last week were immature and unfit for public consumption, one explanation for AGIX’s seemingly odd behavior is that they received a buyout or partnership offer contingent on a peek at the interim data.

Of course, AGIX could have shown the data to a suitor privately, under a non-disclosure agreement. Perhaps AGIX went public to invite a sweetened offer from another suitor.

Or maybe suitors and partners had nothing to do with AGIX’s actions. Nissen and Tardif themselves might have pushed for an early data release in order to bask in the klieg lights. Alternatively, AGIX might have jumped the gun on the pedestrian motive that the company had promised investors a data update during the third quarter and the third quarter was coming to a close.

One thing is for certain: this is going to be a fun one to watch.